AI Shifts Into the Next (Generative) Gear in Healthcare
Riepilogo
Artificial intelligence (AI) has been transforming health and medicine for several decades, whether through diagnostics, personalized medicine, data analytics or other innovations. The advent of generative AI is now reshaping drug discovery, diagnostics, clinical decisions and delivery of care. Traditional healthcare companies — whether healthcare providers, payers, technology partners or pharmaceutical companies — recognize generative AI’s potential. That potential can manifest in the form of faster drug discovery, more accurate diagnostic tools, improved clinical care and patient services, and so on. Each stakeholder is seeking ways to use the technology to their advantage. Medical professionals, patients and regulators are reacting to this new reality, pondering its implications — both promising and troubling — as well as yet-unanswered ethical questions. Health tech and Big Tech join forces on generative AI solutions. Today, traditional health IT and health-tech companies are partnering with tech giants such as Google, Amazon, Microsoft and Meta to bring their generative AI solutions to life. Leading health IT provider Epic’s partnership with Microsoft to integrate generative AI into its electronic health record (EHR) software is a notable example. The takeaway for both industry stakeholders and generative AI users is to watch investor actions. Sustained investor interest will drive the development of stronger, more effective use cases and lead to the emergence of numerous industry- specific generative AI applications in the years ahead. This trend mirrors the introduction of new technologies in previous decades. Startups set the stage for generative AI in healthcare. The generative AI market for healthcare is valued at more than $1 billion as of 2022, and it is projected to swell to almost $22 billion by 2032. Technology giants along with venture capitalists and private equity investors will play a significant role in that market as investors, partners and innovators. These investments stand to benefit tech startups like Abridge, which is working to integrate its generative AI medical note-taking tool with Epic, a move that promises to streamline clinical workflows. Similarly, startup company Basys.ai secured $2.4 million in seed funding to advance its prior authorization tool, which leverages generative AI and deep learning to expedite the insurance preapproval process for medical procedures. Doctors and patients must have a say in shaping generative AI’s role in clinical settings. For every claim of generative AI’s promise made by technology developers, there is often a fear of the unknown held by nearly everyone else, from medical professionals and patients to government officials. Medical professionals can play a crucial role in demystifying that unknown, especially for their patients. As the experts in care, they have earned patients’ trust through decades of experience and will be responsible for using generative AI in the clinical setting. Patients also must be part of the equation because, after all, it is their health that is at stake. Their fears, comfort levels, trust and consent are factors in determining whether and to what extent generative AI should be involved in their treatment.The post AI Shifts Into the Next (Generative) Gear in Healthcare first appeared on PYMNTS.com.
Wio Bank PJSC, the region's first platform bank built to serve tomorrow’s customers, has announced its financial results for the fiscal year 2023, undersc…
Wio Bank PJSC, the region's first platform bank built to serve tomorrow’s customers, has announced its financial results for the fiscal year 2023, underscoring its rapid journey to profitability. As a leading choice for SMEs, the company reported a revenue of AED 266.4 million and a net profit of AED 2 million, marking its first full year of operations with impressive profitability since its launc...
A former managing director at Citigroup is suing the bank and COO for unlawful termination on the grounds of allegedly refusing to provide regulators with…
Ex-Citi employee files wrongful termination lawsuit alleging the bank hid data from regulators
Denaro elettronico
Riepilogo
A former managing director at Citigroup is suing the bank and COO for unlawful termination on the grounds of allegedly refusing to provide regulators with false information.
Raqami Islamic Digital Bank Ltd. (RIDBL), one of five aspirants to the digital retail bank license under the Licensing and Regulatory Framework for Digita…
Raqami Islamic Digital Bank and 1LINK form partnership
Servizi bancari
Riepilogo
Raqami Islamic Digital Bank Ltd. (RIDBL), one of five aspirants to the digital retail bank license under the Licensing and Regulatory Framework for Digital Banks, 2022 is thrilled to announce a strategic partnership with 1LINK, Pakistan’s largest Payment Service Provider / Payment Service Operator. The signing ceremony took place at the 1LINK Office in Park Towers, Karachi and was attended by the...
Orca, a South African startup that works with banks and fintechs in emerging markets to fight various types of fraud, has raised a $550,000 pre-seed round…
Servizi per le aziende · Investimenti · Servizi bancari
Riepilogo
Orca, a South African startup that works with banks and fintechs in emerging markets to fight various types of fraud, has raised a $550,000 pre-seed round. The money raised will be used to build simple, yet effective fraud prevention tools and iterate with customers in South Africa.
The British Business Bank has published the performance data for the third iteration of its Recovery Loan Scheme, highlighting its effectiveness in drivin…
British Business Bank Hails Third Iteration of Recovery Loan Scheme as ‘Important Intervention’
Denaro elettronico
Riepilogo
The British Business Bank has published the performance data for the third iteration of its Recovery Loan Scheme, highlighting its effectiveness in driving growth for UK SMEs. The Recovery Loan Scheme is a government-backed credit guarantee scheme designed to support access to finance for UK businesses looking to invest and grow. Launched in August 2022, the third iteration of the Recovery Loan Scheme, looked to support the British Business Bank’s ongoing commitment to promote sustainable, accessible funding for UK smaller businesses, enabling them to invest and grow. The British Business Bank revealed that the total offered lending for this iteration surpassed £1.3billion, with over 6,000 smaller UK businesses drawing over £1.15billion of finance so far. The scheme aims to help smaller businesses across the UK, with a turnover of up to £45million, access finance they would have been unlikely to access commercially, on equivalent terms. Businesses can use the finance for any ‘legitimate business purpose’, such as managing cashflow, investing in new equipment or vehicles, perhaps to support the transition to net zero, and growth through new products or expansion. However, businesses must be able to afford to take out additional debt finance for these purposes. Overall, the scheme has been a success in targeting the smallest businesses, as the British Business Bank revealed over 90 per cent of the guaranteed facilities supported businesses with under 50 employees. Of this proportion, over 65 per cent of facilities went to businesses with fewer than 10 employees. Delivery working capital across the UK While the scheme supports firms with turnovers of up to £45million, the focus remained on those making less money – over 87 per cent of the guaranteed facilities supported businesses with less than £5million turnover. Reinald de Monchy, managing director of guarantee and wholesale solutions at British Business Bank Reinald de Monchy, managing director of guarantee and wholesale solutions at British Business Bank, said: “The Recovery Loan Scheme was an important intervention at a critical time for UK smaller businesses. What this data publication demonstrates is just how important it has been to delivering growth and working capital across our Nations and regions, and we are looking forward to its transition to the Growth Guarantee Scheme in Summer 2024.” More than half of drawn lending has been designated for business investment and growth purposes, and a third for working capital. The first two phases of the scheme, designed to support access to finance and growth for UK businesses as they recovered from the Covid-19 pandemic, enabled £4.3billion of finance. Jeremy Hunt, the Chancellor of the Exchequer, announced in the Spring Budget 2024 that the scheme, which was due to end on 30 June 2024, would be extended for two years until 31 March 2026, and renamed the Growth Guarantee Scheme. The post British Business Bank Hails Third Iteration of Recovery Loan Scheme as ‘Important Intervention’ appeared first on The Fintech Times.